BeiGene
BGNE
#992
Rank
C$28.36 B
Marketcap
$256.40
Share price
1.55%
Change (1 day)
5.01%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total debt

Total debt on the balance sheet as of September 2024 : C$1.57 Billion

According to BeiGene 's latest financial reports the company's total debt is C$1.57 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BeiGene - Total debt on balance sheet (from 2014 to 2024)

Total debt by year

Year Total debt Change
2023-12-31C$1.23 B52.38%
2022-12-31C$0.80 B-8.54%
2021-12-31C$0.88 B23.55%
2020-12-31C$0.71 B97.82%
2019-12-31C$0.36 B34.03%
2018-12-31C$0.27 B30.51%
2017-12-31C$0.20 B791.58%
2016-12-31C$23.22 M-19.45%
2015-12-31C$28.83 M79.56%
2014-12-31C$16.05 M-44.87%
2013-12-31C$29.12 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
C$0.73 B-53.49%๐Ÿ‡บ๐Ÿ‡ธ USA